Physician profile
Isaac Teitelbaum
NPI 1235229139
$22,174.35
in general payments reported to CMS, 2019-2025
10 companies · $6,322 in 2025
The $6,322 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,660 · 2020: $86.00 · 2021: $5,003 · 2022: $4,103 · 2025: $6,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,300 · Food and Beverage: $21.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,300.00 |
| Food and Beverage | $21.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,510.46 | 2019 | |
| Vantive US Healthcare LLC | $6,300.00 | 2025 | Renal - Pd, Renal - Homechoice Automated Pd, Renal - Extraneal Solution |
| Aurinia Pharma U.S., INC. | $4,882.86 | 2021 | |
| Fresenius USA Marketing, INC. | $3,760.15 | 2022 | |
| Alexion Pharmaceuticals, INC. | $400.00 | 2019-2022 | |
| Vifor Pharma, INC. | $103.41 | 2021 | |
| Glaxosmithkline, LLC. | $93.25 | 2022 | |
| Allergan, INC. | $86.00 | 2020 | |
| Akebia Therapeutics INC | $21.83 | 2025 | Vafseo |
| Nxstage Medical, INC. | $16.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Teitelbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.